|

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

RECRUITINGSponsored by Pell Bio-Med Technology Co., Ltd.
Actively Recruiting
SponsorPell Bio-Med Technology Co., Ltd.
Started2022-12-29
Est. completion2036-12
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05377307

Summary

According to health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) for gene therapy clinical trials, observing subjects for delayed adverse events for 15 years is recommended. This purpose of this long-term follow-up study is to evaluate the safety and efficacy in patients who have ever received lentiviral-based gene-edited immune cells which are manufactured by Pell Bio-Med Technology Co. Ltd.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

1. Patients must have ever received Pell's lentiviral-based gene-edited immune cell as monotherapy or as combination therapy in clinical trials.
2. The last lentiviral-based gene-edited immune cell infusion within 15 years.
3. Patient/patient's parent/legal guardian is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

There are no specific exclusion criteria for this study.

Conditions6

CancerDiffuse Large B-Cell LymphomaFollicular Lymphoma Grade 3AFollicular Lymphoma Grade 3BLarge B-cell LymphomaPrimary Mediastinal Large B-Cell Lymphoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.